Browsing by Author "Laaksonen, M"

Now showing items 1-1 of 1

    • Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 

      Montalban, X; Romero, F; Alonso, A; Tamayo, J; Nos, C; Pelayo, R; Tellez, N; Rio, J; Tintore, M; Arbizu, T; Romero, L; Moral, E; Martinez, S; Kappos, L; Achtnichts, L; Wilmes, S; Karabudak, R; Kurne, A; Erdem, S; Siva, A; Saip, S; Altintas, A; Atamer, A; Bilgili, F; Topcular, B; Giovannoni, G; Lim, ET; Lava, N; Murnane, M; Dentinger, M; Zimmerman, E; Reiss, M; Gupta, V; Scott, T; Brillman, J; Kunschner, L; Wright, D; Perel, A; Babu, A; Rudick, RA; Stuart, WH; Calabresi, PA; Confavreux, C; Galetta, SL; Radue, EW; Lublin, FD; Weinstock-Guttman, B; Wynn, DR; Lynn, F; ERAKSOY, Mefküre; Panzara, MA; Sandrock, AW; Fazekas, F; Enzinger, C; Seifert, T; Storch, M; Strasser-Fuchs, S; Berger, T; Dilitz, E; Egg, R; Deisenhammer, F; Decoo, D; Lampaert, J; Bartholome, E; Bier, J; Stenager, E; Rasmussen, M; Binzer, M; Shorsh, K; Christensen, M; Ravnborg, M; Sorensen, PS; Blinkenberg, M; Petersen, B; Hansen, HJ; Bech, E; Petersen, T; Kirkegaard, M; Eralinna, J; Ruutiainen, J; Soilu-Hanninen, M; Sako, E; Laaksonen, M; Reunanen, M; Remes, A; Keskinarkaus, I; Moreau, T; Noblet, M; Rouaud, O; Couvreur, G; Edan, G; LePage, E; Drapier, S; De Burghgraeve, V; Yaouanq, J; Merienne, M; Cahagne, V; Gout, O; Deschamps, R; Le Canuet, P; Moulignier, A; Vermersch, P; De Seze, J; Stojkovic, T; Griffie, G; Engles, A; Ferriby, D; Debouverie, M; Pittion-Vouyouvitch, S; Lacour, JC; Pelletier, J; Feuillet, L; Suchet, L; Dalecky, A; Tammam, D; Lubetzki, C; Youssov, K; Mrejen, S; Charles, P; Yaici, S; Clavelou, P; Aufauvre, D; Renouil-Guy, N; Cesaro, P; Degos, F; Benisty, S; Rumbach, L; Decavel, P; Confavreux, C; Blanc, S; Aubertin, P; Riche, G; Brochet, B; Ouallet, JC; Anne, O; Menck, S; Grupe, A; Guttman, E; Lensch, E; Fucik, E; Heitmann, S; Hartung, HP; Schroter, M; Kurz, FMW; Heidenreich, F; Trebst, C; Pul, R; Hohlfeld, R; Krumbholz, M; Pellkofer, H; Haas, J; Segert, A; Anagnostou, P; Meyer, R; Kabus, C; Poehlau, D; Schneider, K; Hoffmann, V; Zettl, U; Steinhagen, V; Adler, S; Steinbrecher, A; Rothenfusser-Korber, E; Zellner, R; Baum, K; Gunther, A; Blasing, H; Stoll, G; Gold, R; Bayas, A; Kleinschnitz, C; Limmroth, V; Katsarava, Z; Kastrup, O; Haller, P; Stoeve, S; Hobel, D; Oschmann, P; Voigt, K; Burger, CV; Abramsky, O; Karusiss, D; Achiron, A; Kishner, I; Stern, Y; Sarove-Pinhas, I; Dolev, M; Magalashvili, D; Pozzili, C; Lenzi, D; Scontrini, A; Millefiorini, E; Buttinelli, C; Gallo, P; Ranzato, F; Tiberio, M; Perini, P; Laroni, A; Marrosu, M; Marchi, ECP; Spinicci, G; Massole, S; Mascia, M; Floris, G; Trojano, M; Bellacosa, A; Paolicelli, D; Zimatore, GB; Simone, IL; Giorelli, M; Di Monte, E; Mancardi, G; Pizzorno, M; Murialdo, A; Narciso, E; Capello, A; Comi, G; Martinelli, V; Rodegher, M; Esposito, F; Colombo, B; Rossi, P; Polman, CH; Jasperse, MMS; Zwemmer, JNP; Nielsen, J; Kragt, JJ; Jongen, PJH; De Smet, E; Tacken, H; Frequin, STFM; Siegers, HP; Mauser, HW; Fernandez-Fernandez, O; Leon, A (2006)
      .AbstractBackgroundInterferon beta is used to modify the course of relapsing multiple sclerosis. Despiteinterferon beta therapy, many patients have relapses. Natalizumab, an α4 integrinantagonist, appeared to be safe and ...